TTNP: Titan Pharmaceuticals Inc. Earnings per share for the last twelve months

Corporate company logo of titanpharm.com (TTNP)

Titan Pharmaceuticals relies on ProNeura technology for the treatment of Parkinson's disease and addictions, which serves as the primary growth catalyst. Niche protection is ensured by patents and stringent FDA requirements, while product output is managed through calibrated partner capacities. The trailing 12-month net income per share clearly demonstrates the effectiveness of this strategy, where -2.96 represents the current metric value.

Titan Pharma (TTNP) - Earnings per share for the last four quarters from 07/04/2022 to 10/18/2025

Titan Pharma (TTNP) - metric breakdowns and financial figures

- current quotes and average value forecast:
Analysis of all company metrics:TTNP - Titan Pharmaceuticals
Flagship merchandise of Titan Pharmaceuticals Inc.

The stability of Titan Pharmaceuticals (TTNP) is driven by the deep expertise of its scientists in developing implantable drug delivery systems. By analyzing the trailing twelve-month (TTM) EPS, an investor can see the net profit allocated per share over a year. The trend of this metric reflects the actual scalability of the business between quarterly reports. An upward trajectory confirms the effectiveness of development, while stagnation signals a limit to expansion. This trend determines the fair value of the asset.